Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023 Nov 7, 2023
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Oct 24, 2023
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023 Aug 4, 2023
Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials Apr 20, 2023
